|Dr. Barry D. Quart Pharm.D.||Chief Exec. Officer & Director||795.59k||76.26k||60|
|Mr. Robert H. Rosen||Pres & Director||787.63k||4.82M||61|
|Ms. Kimberly J. Manhard||Exec. VP of Drug Devel.||544.74k||N/A||57|
|Mr. Robert E. Hoffman||Chief Financial Officer and Sr. VP of Fin.||N/A||N/A||51|
|Ms. Jennifer Capuzelo||Associate Director of Investor Relations||N/A||N/A||N/A|
Heron Therapeutics, Inc., a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single subcutaneous injection. It offers SUSTOL (granisetron) extended-release injection for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens. The company is also developing CINVANTI (HTX-019), a neurokinin-1 receptor antagonist for the prevention of CINV; and HTX-011, which is in Phase II clinical development for the prevention of post-operative pain. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
Heron Therapeutics, Inc.’s ISS Governance QualityScore as of February 1, 2018 is 7. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 1; Compensation: 8.